Somatropin inhaled - Aerami Therapeutics
Alternative Names: Aerami 801Latest Information Update: 28 Oct 2023
At a glance
- Originator Dance Biopharm
- Developer Aerami Therapeutics
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Somatotropin-deficiency in USA (Inhalation, Liquid)
- 25 Sep 2019 Dance Biopharm is now called Aerami Therapeutics
- 19 Sep 2019 Dance Biopharm announces intention to submit IND to US FDA for Somatotropin deficiency in 2020 (Dance Biopharm pipeline, September 2019)